Sandoz announces launch of pramipexole dihydrochloride tablets, a generic version of Mirapex®

Sandoz announces launch of pramipexole dihydrochloride tablets, a generic version of Mirapex®
Princeton, New Jersey, October 13, 2010 - Sandoz announced today the launch of pramipexole dihydrochloride tablets, a generic equivalent of Mirapex®, in the US. Pramipexole dihydrochloride tablets are indicated for the treatment of the signs and symptoms of idiopathic Parkinson's disease.

At least 500,000 people are believed to suffer from Parkinson's disease in the US, with about 50,000 new cases reported annually [1].
According to IMS Health, Mirapex® had US sales of approximately USD 529 million for the 12 months ending August 2010. Sandoz is marketing pramipexole dihydrochloride tablets in 0.125 mg, 0.25 mg, 0.5, 0.75 mg, 1 mg and 1.5 mg strength tablets, the same as Mirapex®.

Disclaimer
The foregoing release contains forward-looking statements that can be identified by terminology such as "launch," or similar expressions, or by express or implied discussions regarding potential future revenues from pramipexole dihydrochloride tablets. You should not place undue reliance on these statements. Such forward-looking statements reflect the current views of the Company regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that pramipexole dihydrochloride tablets will achieve any particular levels of revenue in the future. In particular, management's expectations could be affected by, among other things, unexpected inabilities by generic manufacturers to obtain or maintain exclusivity periods for generic pramipexole dihydrochloride tablets; competition in general; government, industry and general public pricing pressures; unexpected patent litigation outcomes; unexpected regulatory actions or delays or government regulation generally; the impact that the foregoing factors could have on the values attributed to the Novartis Group's assets and liabilities as recorded in the Group's consolidated balance sheet, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Sandoz
Sandoz, a Division of the Novartis group, is a global leader in the field of generic pharmaceuticals, offering a wide array of high-quality, affordable products that are no longer protected by patents. Sandoz has a portfolio of about 1000 compounds and sells its products in more than 130 countries. Key product groups include antibiotics, treatments for central nervous system disorders, gastrointestinal medicines, cardiovascular treatments and hormone therapies. Sandoz develops, produces and markets these medicines along with pharmaceutical and biotechnological active substances and anti-infectives. In addition to strong organic growth in recent years, Sandoz has made a series of acquisitions including Lek (Slovenia), Sabex (Canada), Hexal (Germany), Eon Labs (US), EBEWE Pharma (Austria) and Oriel Therapeutics (US). In 2009, Sandoz employed around 23,000 people worldwide and posted sales of USD 7.5 billion.
References
[1] National Institute of Neurological Disorders and Stroke. Parkinson's Disease Backgrounder. Available from: http://www.ninds.nih.gov/disorders/parkinsons_disease/parkinsons_disease_backgrounder.htm.
* * *
For further information
Sandoz US Communications:
Ted Deutsch
+1 609 627 5287
Sandoz Global Communications:
Marija Mandic
+49 8024 476 2597
Mirapex® is a registered trademark of Boehringer Ingelheim International GmbH.

Suggested Articles

WuXi AppTec has appointed Celgene CAR-T program veteran David Chang to lead its cell and gene therapy CDMO, WuXi Advanced Therapies.

Maryland-based Emergent BioSolutions has won a $628 million contract with BARDA to manufacture targeted COVID-19 vaccine hopefuls.

About 76% remdesivir patients had at least one point of clinical improvement on a 7-point scale at day 11, versus 66% of patients on standard care.